ライフサイエンスコーパス: receptor agonist

1 istension that could be rescued with GABA(B) receptor agonist.

2 on induced by thermal pain or a kappa opioid receptor agonist.

3 the A-ring in its activity as a kappa-opioid receptor agonist.

4 was achieved following treatment with a THPO receptor agonist.

5 ectified by chronic administration of a TrkB receptor agonist.

6 mice was rescued by administration of an OT receptor agonist.

7 as previously reported to be a selective CB2 receptor agonist.

8 y profile consistent with subcutaneous GLP-1 receptor agonists.

9 EG-b-PLA) nanoparticles for use as adenosine receptor agonists.

10 s of biphenyl acid derivatives as potent APJ receptor agonists.

11 for the distal carboxylic acid in glutamate receptor agonists.

12 re on the therapeutic performance of mGlu2/3 receptor agonists.

13 ) -activated K(+) current (BK) by purinergic receptor agonists.

14 ls that can be activated by beta3-adrenergic receptor agonists.

15 has the potential to perform better than sst receptor agonists.

16 brain-state switching when exposed to GABAA-receptor agonists.

17 ent and injury, and is promoted by serotonin receptor agonists.

18 activation of PLC signaling by D1 and mGlu5 receptor agonists.

19 for the screening and discovery of novel P2X receptor agonists.

20 kinesia in animals treated with L-DOPA or D1 receptor agonists.

21 FNs promoted enhanced responses to Toll-like receptor agonists.

22 ective effects of an alpha-1A-AR (adrenergic receptor) agonist.

23 iet or by applying topical TLR7/8 (Toll-like receptor) agonists.

24 The physiologic vitamin D receptor agonist, 1,25(OH)2D3 (calcitriol), is synthesiz

25 ns of GABA-A (muscimol) or GABA-B (baclofen) receptor agonists 15 to 20 minutes prior to injection of

26 demonstrates that the endogenous cannabinoid receptor agonists 2-arachidonoylglycerol (2-AG) and anan

27 habditis elegans, the endogenous cannabinoid receptor agonist, 2-arachidonoylglycerol (2-AG) activate

28 PET imaging with the dopamine D(2) and D(3) receptor agonist 3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2

29 The GHB receptor agonist 3-chloropropanoic acid and the antagoni

30 orum brevis (FDB) fibers, either a ryanodine receptor agonist (4-chloro-meta-cresol) or depolarizing

31 The arylhydrocarbon receptor agonist 6-formylindolo[3,2-b] carbazole (FICZ),

32 how that intra-mPFC infusion of the 5-HT(1A) receptor agonist 8-OH-DPAT induces rapid and long-lastin

33 tonin (5-HT)2C receptor antagonists, a 5-HT4 receptor agonist, a 5-HT7 receptor antagonist, NMDA rece

34 also prevents hyperalgesia induced by a CD44 receptor agonist, A6.

35 Adiponectin receptor agonists abrogated ex vivo fibrotic responses i

36 demonstrate that, unlike other bitter-taste receptor agonists, absinthin alone (1 mum) in ASM cells

37 ate metabolism induced by the nicotinic acid receptor agonist, Acipimox, using hyperpolarized Carbon-

38 We found that the G protein-coupled receptor agonists adenosine triphosphate (ATP) and hista

39 y, we applied a newly discovered adiponectin receptor agonist AdipoRon (APR) in experimental periodon

40 ly analysed the efficacy and safety of a CB1-receptor agonist administered in six patients with refra

41 Treatment with an apelin receptor agonist after vasculopathy was established mark

42 Although soluble receptor agonist alone could not induce death, combinato

43 cells from MM patients primed with the IL-15 receptor agonist ALT-803 in vivo displayed enhanced ex v

44 n the benzyl ring of the abscisic acid (ABA) receptor agonist AM1 optimizes its binding to ABA recept

45 okinin, exendin-4 (a glucagon-like peptide-1 receptor agonist), amylin, and mechanical distension of

46 In vitro, an apelin receptor agonist analog elicited endothelial nitric oxid

47 prevented by pretreatment with an mGlu(2/3) receptor agonist and absent in mice lacking the Grm2, bu

48 ptide - METx - is a selective competitive V2 receptor agonist and an anti-diuretic.

49 varial cells, an effect that was modified by receptor agonist and antagonist treatment.

50 vels alone and in combination with nicotinic receptor agonist and antagonists resulted in cell specif

51 Salvinorin A (SA) is a kappa-opioid receptor agonist and atypical dissociative hallucinogen

52 endin-4 is a glucagon-like peptide-1 (GLP-1) receptor agonist and potent insulinotropic agent for typ

53 Cheap, simple ammonium salts act as sigma-1 receptor agonists and antagonists in vivo and require fu

54 dynamics, and their modulation by nicotinic receptor agonists and antagonists, were assessed using f

55 motions during binding of a range of 5-HT(3) receptor agonists and antagonists.

56 glitazones), glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhi

57 ensitizing peroxisome proliferator-activated receptor agonists and inhibited by tumor necrosis factor

58 Activation of PMs by Toll-like receptor agonists and live bacteria altered levels of CD

59 n may be crucial for glucagon-like peptide-1 receptor agonists and other antihyperglycemic agents.

60 r the influence of CXCR1 and CXCR2 chemokine receptor agonists and other chemotactic factors produced

61 ) elevations in response to neurotransmitter receptor agonists and RNA sequencing of the same single

62 Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 in

63 nts have recommended glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter type

64 Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SG

65 Widely used antidiabetic drugs (GLP-1 receptor agonists and sulfonylureas) activate this pathw

66 atients' CSF did not alter responses to AMPA receptor agonists and was abrogated by preabsorption of

67 inhibited by idremcinal, a macrolide motilin receptor agonist, and by synthesized macrolide derivativ

68 ural compound known to function as an opioid-receptor agonist, and is undergoing clinical trials for

69 raglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, and phentermine, a psychostimulant str

70 ptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, and sodium-glucose cotransporter 2 inh

71 from normal human liver, incubated with LTB receptor agonist, and transfected with small interfering

72 1 receptors, beta-arrestin-based Angiotensin receptor agonists, and administration of soluble ACE2 or

73 by 4-aminopyridine and inhibited by GABA(B) receptor agonists, and appears far more sensitive to the

74 inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists, and sodium-glucose cotransporter 2 [S

75 utic drug classes, namely the ditans: 5-HT1F receptor agonists, and the gepants: calcitonin gene-rela

76 The effects of oxytocin, selective oxytocin receptor agonists, antagonists, and vehicle injected int

77 closerine/dextromethorphan), dopamine type 2 receptor agonists/antagonists (bromocriptine/haloperidol

78 92 healthy participants received either NMDA receptor agonists/antagonists (D-cycloserine/dextrometho

79 Certain A(3) adenosine receptor agonists are being developed for the treatment

80 e-presented CD40 ligand (mCD40L), as soluble receptor agonists are but weakly pro-apoptotic.

81 Muscarinic receptor agonists are characterized by apparently strict

82 Nucleic acid-based pattern recognition receptor agonists are effective adjuvants and immunother

83 Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs.

84 Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatm

85 Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for type 2 di

86 Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of gastr

87 Galpha(s)-coupled receptor agonists are known to have immunosuppressive ef

88 the new statements, glucagon-like peptide-1 receptor agonists are suggested treatment not only for p

89 Notably, cannabinoid receptor agonists as well as inhibitors of endocannabino

90 Application of either GABA(A) or GABA(B) receptor agonists attenuated the colonic afferent respon

91 n-angiotensin system with the nonpeptide Mas receptor agonist AVE 0991 holds promise for reducing mus

92 The GABAB receptor agonist baclofen also inhibited inward currents

93 The orthosteric GABAB receptor agonist baclofen has been shown to suppress ope

94 ty of SOM-IPSCs, but not PV-IPSCs to a GABAb receptor agonist baclofen.

95 G(i/o)-biased and beta-arrestin2-biased D(2) receptor agonists based on the Food and Drug Administrat

96 adenosine receptor agonist NECA and the A2B receptor agonist BAY60-6583.

97 euronally directed effects of the retinoid X receptor agonist bexarotene in an aggressive model of AD

98 h the pan-peroxisomal proliferator-activated receptor agonist, bezafibrate, to determine the drug's e

99 nergic modulation with a placebo, a dopamine receptor agonist bromocriptine or a dopamine receptor an

100 d the effects of the mu opioid peptide (MOP) receptor agonist buprenorphine and the buprenorphine ana

101 ha,beta-methylene ATP (alpha,beta-meATP, P2X receptor agonist), but not ADP (P2Y receptor agonist), c

102 trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular effica

103 Selective D4 receptor agonists, by specifically targeting these termi

104 These results also suggested that a receptor agonist can be switched to an antagonist by sub

105 or necrosis factor (TNF) or lymphotoxin-beta receptor agonist can rescue expression of Erap1, Tap1 an

106 loserine (DCS), which is a glycine site NMDA receptor agonist, can enhance extinction of conditioned

107 f Ser-2808 in RyR2 induced by the muscarinic receptor agonist carbachol is mediated by a signaling ax

108 phoretically applied the general cholinergic receptor agonist carbachol onto neurons in dorsolateral

109 show cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials and sugge

110 ATP, P2X receptor agonist), but not ADP (P2Y receptor agonist), caused a graded increase in mean arte

111 n bronchi precontracted by carbachol, the IP receptor agonist cicaprost induced profound relaxation.

112 eratures or treated with the beta-adrenergic receptor agonist CL316,243 and that its expression is in

113 Treatment with the beta3-adrenergic receptor agonist CL316,243 increased Cx43 expression and

114 role of Tregs in enhancing beta3-adrenergic receptor agonist CL316243 (CL)-stimulated thermogenic pr

115 renal safety, was consistent with the GLP-1 receptor agonist class.

116 at assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patient

117 dscape associated with the activation of the receptor-agonist complex and comparing it with that obta

118 Translocation of receptor-agonist complexes to the signaling region and l

119 ntly as a functionally selective dopamine D2 receptor agonist contributing potentially to the rewardi

120 Our studies show that GDNF and its receptor agonists could be useful for enhancing hepatocy

121 We propose that G protein-biased mu opioid receptor agonists, currently in development as analgesic

122 ng inhibition of cAMP signaling by mu-opioid receptor agonists DAMGO and morphine.

123 out as the most potent and selective LPA(1) receptor agonist described so far (E(max) = 118%, EC(50)

124 The only approved AVP receptor agonist, desmopressin is indicated for the trea

125 METx forms nanofibers and is a partial V2 receptor agonist (determined by measuring MDCK cell line

126 ulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 d

127 Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration

128 between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as

129 We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovasc

130 e assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exp

131 d with increased levels of Galpha(s)-coupled receptor agonists (e.g., tumor growth, malaria, hypoxia,

132 The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibr

133 s (eg, buprenorphine), and alpha2-adrenergic receptor agonists (eg, clonidine and lofexidine).

134 withdrawal include treatment with mu-opioid receptor agonists, (eg, methadone), partial agonists (eg

135 acetyl cysteine (NAC) and the 5-HT(1B/1D/1F) receptor agonist eletriptan to normalise the behavioural

136 ed that systemic administration of the GLP-1 receptor agonist exendin-4 reduced oxycodone self-admini

137 Cotreatment with the GLP-1 receptor agonist exendin-4 reversed the lysosomal dysfun

138 t that cibinetide, a selective innate repair receptor agonist, exerts islet protective and antiinflam

139 dministration of the high-efficacy mu opioid receptor agonist fentanyl and characterized MCAM pharmac

140 We have shown previously that the S1P receptor agonist fingolimod (FTY720) attenuates psychosi

141 e first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with

142 The therapeutic success of peptidic GLP-1 receptor agonists for treatment of type 2 diabetes melli

143 o assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (grade 4) treatme

144 ocally concentrating and releasing a GABA(A) receptor agonist from ultrasound-controlled carriers.

145 elanocortin system consists of five reported receptors, agonists from the proopiomelanocortin gene tr

146 with that obtained with the ternary complex (receptor-agonist-G protein) we show that the agonist sta

147 egimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) added to metformin-based b

148 on occurred, and for glucagon-like peptide-1 receptor agonists (GLP-1 RAs; 3.0%) using three methodol

149 Several glucagon-like peptide receptor agonists (GLP-1RA) and sodium-glucose cotranspo

150 INT-777 (50 muM), but not by the farnesoid X receptor agonist, GW4064 (10 muM).

151 NK(1) receptor agonists had minimal effects on ICC-IM, whereas

152 Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascul

153 ate, a pan-peroxisome proliferator-activated receptor agonist, has been shown to ameliorate deranged

154 Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histolog

155 -4 (EX-4), a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to reduce food intake a

156 Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclin

157 anate, a first-in-class partial adenosine A1 receptor agonist, has the potential to improve several h

158 hibitors and GLP-1 (glucagon-like peptide-1) receptor agonists, has changed the landscape of therapeu

159 GLP-1 receptor agonists have a favourable risk-benefit balance

160 ter 2 inhibitors and glucagon-like peptide 1 receptor agonists have consistently shown safety and red

161 Nicotinic acid receptor agonists have previously been shown to cause ac

162 nicotinic alpha-7 acetylcholine (nalpha(7)) receptor agonists, have largely failed to demonstrate ef

163 ompounds such as BIM-23A760, an sst2/sst5/D2 receptors-agonist, have emerged as promising new approac

164 of-of-concept for the discovery of novel P2X receptor agonists, here we demonstrate the use of Drosop

165 administered the growth hormone secretagogue receptor agonist HM01 or vehicle.

166 A separate concern is that benzodiazepine receptor agonist hypnotics can cause parasomnias, which

167 uding the inflammation markers interleukin-1 receptor agonist (IL-1RA) and high-sensitivity C-reactiv

168 nclusion, we demonstrate that nicotinic acid receptor agonists impair cardiac contractility associate

169 OT neuron number and administration of an OT receptor agonist improved social deficits.

170 erone or fluvoxamine, a high-affinity sigma1-receptor agonist, improved survival, renal function and

171 d conditions, chronic administration of a D1 receptor agonist in conjunction with fluoxetine restores

172 ormerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients without cirrhosis with larg

173 The GRIPHON trial (Prostacyclin [PGI(2)] Receptor Agonist In Pulmonary Arterial Hypertension) pro

174 However, the efficacy of GLP-1 receptor agonists in attenuating opioid-mediated behavio

175 the psychotomimetic effects of kappa opioid receptor agonists in healthy volunteers and their revers

176 tive effects with SGLT2 inhibitors and GLP-1 receptor agonists in patients with CKD and T2D.

177 regarding effects of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes (T2D)

178 in combination with glucagon-like peptide-1 receptor agonists in preclinical models.

179 e reference compound, (68)Ga-DOTATOC (an sst receptor agonist), in PET imaging.

180 or fibroblastic cells with G protein-coupled receptor agonists, including angiotensin II or bombesin,

181 ts and mechanism(s) of action of cannabinoid receptor agonists, including Delta9-THC, on inflammation

182 significantly potentiated the effects of CB2 receptor agonists, including the endocannabinoid 2-arach

183 peated intra-BLA injections of NPY or a Y(5) receptor agonist increased social interaction, a validat

184 Consequently, a selective BLT2-receptor agonist increased thermal and mechanical withdr

185 We also show that a PGE2 receptor agonist increased, whereas a PGE2 synthase inhi

186 thermore, in NOP-eGFP and NOP-eYFP mice, NOP receptor agonists induced multisite phosphorylation and

187 Intranasal exposure with receptor agonists induced the release of IL-33 and subse

188 hat 5-hydroxytryptamine receptor (5HTR)1A/1B receptor agonists inhibit biliary hyperplasia in bile-du

189 Both singular EP2 and EP4 receptor agonists inhibited HASM proliferation, and comb

190 ritis using butyrate or a cannabinoid type 1 receptor agonist inhibits the development of arthritis.

191 by microinjection of small amounts of GABAA-receptor agonists into an upper brainstem region named t

192 f the highly potent muscarinic acetylcholine receptor agonist iperoxo.

193 Endothelin-B receptor agonist, IRL-1620, provides significant neuropr

194 ddicted pregnant women on long-acting opioid receptor agonist is the most common strategy to manage d

195 plasticity and intranasal treatment with C3a receptor agonists is an attractive approach to improve f

196 roughout the body, obtaining highly specific receptor agonists is essential.

197 Selepressin, a selective vasopressin V1a receptor agonist, is a noncatecholaminergic vasopressor

198 Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of obesity;

199 integrins-we show that the Galpha(s)-coupled receptor agonists isoproterenol, epinephrine, norepineph

200 egularly used long-acting beta(2)-adrenergic receptor agonist (LABA) is well documented.

201 ination with a long-acting beta2 -adrenergic receptor agonist (LABA) on GCM in the bronchial epitheli

202 ion, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically significant increase

203 The opioid receptor agonist, leu-enkephalin, was predicted to have

204 e the effects of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanz

205 dence shows that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduces the r

206 More recently, the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide also reduc

207 ed via HDAC2 the capabilities of the mGlu2/3 receptor agonist LY379268 to activate G-proteins in the

208 ketamine and (2R,6R)-HNK prevented mGlu(2/3) receptor agonist (LY379268)-induced body temperature inc

209 additional proof of principle that an apelin receptor agonist may be of therapeutic use in PAH in hum

210 Although glucagon-like peptide-1 receptor agonists may be appropriate to use in patients

211 dulators of cardiovascular function, and APJ receptor agonists may be beneficial in the treatment of

212 rsistent inflammation and that selective CB2 receptor agonists may be useful for treatment of persist

213 suggests that differential signaling by NOP receptor agonists may play a role in NOP receptor ligand

214 ation and propose that selective EP2 and EP4 receptor agonists might serve as a promising therapeutic

215 tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in improving thromb

216 e used local infusion of GABA(A) and GABA(B) receptor agonists (muscimol + baclofen) to show a causal

217 ect of inosine was mimicked by the adenosine receptor agonist NECA and the A2B receptor agonist BAY60

218 boline, an anxiogenic inverse benzodiazepine receptor agonist, normalized alcohol preference in EFhd2

219 G49, a dual glucagon-like peptide-1/glucagon receptor agonist, on NASH and hepatic regeneration.

220 arget organ, exogenous administration of AT2 receptor agonists or angiotensin 1-7 analogs may similar

221 enhanced the promoting effect of Muscarinic receptor agonist oxotremorine-M on insulin secretion in

222 ng of a Toll-like receptor and C-type lectin receptor agonist pairing that significantly increases pr

223 r administration of oxytocin or the oxytocin receptor agonist PF-06655075, which does not cross the b

224 limited to medications (e.g., the muscarinic receptor agonists pilocarpine and cevimeline) that induc

225 us cells, mutant receptors had enhanced NMDA receptor agonist potency and slow deactivation following

226 ive EP2 agonist and, to a lesser extent, EP4 receptor agonist potentiated LPS-induced IL-33 generatio

227 e shown that glucagon-like peptide 1 (GLP-1) receptor agonists prevent beta-cell loss.

228 Furthermore, the 5-HT(4) receptor agonist prucalopride increases enteric neurogen

229 demonstrate the utility of the novel 5-HT2A receptor agonist radioligand, [(11)C]CIMBI-36, and a d-a

230 Liraglutide is a GLP-1 receptor agonist recently approved for Type-II diabetes

231 ee different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in peop

232 dicates that glucagon-like peptide-1 (GLP-1) receptor agonists reduce drug reinforcement.

233 Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with

234 Eltrombopag (ELT) is a thrombopoietin receptor agonist reported to decrease labile iron in leu

235 safety profile to currently available GLP-1 receptor agonists, representing a potential treatment op

236 nist alone or concurrently with somatostatin receptor agonists represents a potential therapeutic app

237 istration of lithocholic acid or a vitamin D receptor agonist resulted in increased Slc30a10 expressi

238 A comparison of structurally distinct NOP receptor agonists revealed dissociation in functional ef

239 nancy while on treatment with thrombopoietin receptor agonists, rituximab, or mycophenylate, which po

240 ncy of the dual GCGR/glucagon like peptide-1 receptor agonist SAR425899.

241 The selective NOP receptor agonist SCH 221510 also selectively decreased e

242 d proliferation of new synthetic cannabinoid receptor agonists (SCRAs) has initiated considerable int

243 Synthetic cannabinoid receptor agonists (SCRAs), termed "Spice" or "K2", are m

244 utaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral sem

245 Type 1 mGluR5 activation increases TRPA1 receptor agonist sensitivity in an AKA-dependent manner.

246 The application of glucagon-like peptide one receptor agonists, specific PD gene target agents (such

247 of the lipid mediator and G protein-coupled receptor agonist sphingosine-1-phosphate (S1P).

248 Eltrombopag, an oral thrombopoietin receptor agonist, stimulates platelet production by a si

249 IFICANCE STATEMENT Clinically used mu-opioid receptor agonists such as fentanyl can produce hyperalge

250 Dual-acting glucagon-like peptide-1/glucagon receptor agonists such as G49 represent a novel therapeu

251 esearch into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for

252 iiodothyronine and synthetic thyroid hormone receptor agonists, such as sobetirome (GC-1), are known

253 n were rectified by administration of a TrkB receptor agonist, suggesting reduced BDNF-TrkB signaling

254 or phosphorylation by chemically diverse NOP receptor agonists suggests that differential signaling b

255 n and AdipoRon, a small-molecule adiponectin receptor agonist, suppress colon cancer risk in part by

256 s were not affected by apyrase, or by the P2 receptor agonists suramin (150 mum) or PPADS (50 mum) bu

257 Two potent sigma(1) receptor agonists, TC1 and SA4503, showed dose-dependent

258 tment with a peripherally restricted GABA(A) receptor agonist that acts directly on mechanosensory ne

259 L-10) is a first-in-class, long-acting IL-10 receptor agonist that induces oligoclonal T-cell expansi

260 Lorcaserin, a selective serotonin 2C receptor agonist that promotes appetite suppression, led

261 the P-gp interaction of some A(3) adenosine receptor agonists that are being developed for the treat

262 of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat m

263 lipidized peptide arginine vasopressin (AVP) receptor agonist, that had not been designed as a prodru

264 uated in the presence of GABA(A) and GABA(B) receptor agonists, the VMR was only consistently increas

265 entially lead to earlier initiation of GLP-1 receptor agonist therapy in the diabetes treatment conti

266 cy of a short-course glucagon-like peptide-1 receptor agonist therapy-specifically 2-quinoxalinamine,

267 efit from the addition of a beta2-adrenergic receptor agonist to their medication.

268 a therapeutic strategy to deliver nucleotide receptor agonists to effectively rehydrate the ASL of CF

269 h glitazones or DPP4 inhibitors and/or GLP-1 receptor agonists to individuals treated with other anti

270 Thrombopoietin receptor agonists (Tpo-RAs), which likely cross the plac

271 Correspondingly, adenosine receptor agonist treatment also limited HDM-driven aller

272 ullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.

273 GLP-1 receptor agonist treatment reduced all-cause mortality b

274 Overall, GLP-1 receptor agonist treatment reduced MACE by 12% (HR 0.88,

275 Compared with placebo, GLP-1 receptor agonist treatment showed a significant 10% rela

276 Combining D2 receptor agonist treatment with rM3Ds-dSPN stimulation r

277 an emerging view that NAC, or 5-HT(1B/1D/1F) receptor agonist treatment, may be a promising strategy

278 renorphine or the G protein-biased mu opioid receptor agonist TRV130.

279 telet aggregation induced by the thromboxane receptor agonist U46,619, and this effect was abrogated

280 condition of low levels of Galpha(s)-coupled receptor agonists, up-regulates integrin activation comp

281 Salmeterol is a long-acting beta2-adrenergic receptor agonist used to treat chronic obstructive pulmo

282 Treatment with vitamin D receptor agonists (VDRAs) may have nephroprotective and

283 exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) versus placebo on the rates of the pri

284 Additionally, an adenosine receptor agonist was tested to study the mechanism of su

285 No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal

286 acokinetics study demonstrated adipoRon (APN receptor agonist) was a blood-brain barrier penetrant.

287 Lasmiditan, a serotonin 5-HT1F receptor agonist, was effective for acute treatment of p

288 Cys(40)-Exendin-4, a glucagon-like peptide 1 receptor agonist, was evaluated as a potential PET trace

289 Thus, we examined the effects of a 5-HT2C receptor agonist, WAY163909, and a 5-HT2A receptor antag

290 hich structural features define an active JH receptor agonist, we tested several native JHs and their

291 ic reaction to the application of the amylin receptor agonist were observed in male and female mice.

292 r trials of cardiovascular outcomes of GLP-1 receptor agonists were identified: ELIXA (lixisenatide),

293 GES-1-null and WT bmMFs, whereas EP1 and EP3 receptor agonists were inactive.

294 landin dehydrogenase inhibitor or EP2 or EP4 receptor agonists were used in a murine model of passive

295 ration (SA), using the synthetic cannabinoid receptor agonist WIN55,212-2 (WIN), in order to assess m

296 Paradoxically, the nonselective CB1/CB2 receptor agonist WIN55212 inhibited GABAergic mIPSCs in

297 ave reported on the concomitant use of GLP-1 receptor agonists with sodium-glucose cotransporter-2 (S

298 efficacy and safety of semaglutide (a GLP-1 receptor agonist) with canagliflozin (an SGLT2 inhibitor

299 unoglobulin within 2 weeks or thrombopoietin receptor agonists within 4 weeks before randomisation we

300 he most potent small-molecule Ins(1,4,5)P(3) receptor agonist without a nucleobase yet synthesized.